ClinicalTrials.gg
CompletedNCT02262741Updated Oct 23, 2017

A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer

A Phase 1 interventional study of MEDI4736 and tremelimumab in Squamous Cell Carcinoma of the Head and Neck, sponsored by MedImmune LLC. Completed at 23 sites in 2 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2017-10-23.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
71
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing durvalumab in Squamous Cell Carcinoma of Head and Neck — none open to participants now, 3 under way, none of them phase 3. durvalumab · Squamous Cell Carcinoma of Head and Neck.

Enrollment
7th of 20
71 · median 40
Started
2014
the only one that year
Phase 1
7 of 20
none open now
Registered
2nd of 20
by date

Among the 20 studies testing durvalumab in Squamous Cell Carcinoma of Head and Neck, this one is the 7th largest by enrollment, is the only one that started in 2014, is one of 7 in phase 1, and was the 2nd registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

None of the 20 studies testing durvalumab in Squamous Cell Carcinoma of Head and Neck is open now. The open studies under Squamous Cell Carcinoma of Head and Neck, anywhere →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing durvalumab in Squamous Cell Carcinoma of Head and Neck as a file.
02

Study summary

This is a multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and immunogenicity of MEDI4736 in combination with tremelimumab in subjects with recurrent/metastatic squamous cell carcinoma of the head and neck.

03

Conditions studied

  • Squamous Cell Carcinoma of the Head and Neck
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female subjects
  2. 18 years and older
  3. or cytologically confirmed recurrent or squamous cell carcinoma of the head and neck (oral cavity, oropharynx, hypopharynx or larynx) that is incurable by local therapy.
  4. Subjects who are treatment-naive or pretreated (prior or anti-PD-L1 required) in the recurrent/metastatic setting.
  5. Subject eligibility will be based on PD-L1 expression as determined by a specified IHC assay.

Exclusion criteria

Exclusion Criteria:

  1. Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment, receipt of last dose of an approved anticancer therapy within 21 days
  2. Concurrent or prior use of medication within 14 days
  3. Active or prior documented or inflammatory disease within 3 years with some exceptions.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    MEDI4736 + tremelimumab

    Biological: MEDI4736 · Biological: tremelimumab

Interventions

  • BiologicalMEDI4736

    MEDI4736 will be administered by IV infusion in combination with tremelimumab.

  • Biologicaltremelimumab

    Tremelimumab will be administered by IV infusion in combination with MEDI4736.

06

What researchers measure

Primary outcomes

  1. Number of subjects reporting adverse events

    Time frame: Screening through 3 months after the last dose of study medication

  2. Number of subjects reporting serious adverse events

    Time frame: Screening through 3 months after the last dose of study medication

  3. Number of subjects experiencing dose-limiting toxicities

    Time frame: First dose of study medications through 4 weeks after the first dose of study medication

  4. Change from Baseline in laboratory evaluations

    Time frame: Screening through 3 months after the last dose of study medication

  5. Change from Baseline in electrocardiograms

    Time frame: Screening through 3 months through last dose of study medication

  6. Change from Baseline in vital signs

    Time frame: Screening through 3 months after the last dose of study medication

Secondary outcomes

  1. Objective Response Rate

    Time frame: Screening through 5 years after the last subject receives the first dose of study medication

  2. Individual MEDI4736 concentrations

    Time frame: First dose of MEDI4736 through 3 months after the last dose of study medication

  3. Number of subjects that develop changes in detectable antidrug antibodies to MEDI4736

    Time frame: First dose of MEDI4736 through 6 months after the last dose of study medication

  4. Disease Control Rate

    Time frame: Screening through 5 years after the last subject receives the first dose of study medication

  5. Duration of Response

    Time frame: Screening through 5 years after the last subject receives the first dose of study medication

  6. Progression Free Survival

    Time frame: Screening through 5 years after the last subject receives the first dose of study medication

  7. Overall Survival

    Time frame: Screening through 5 years after the last subject receives the first dose of study medication

  8. Individual tremelimumab concentrations

    Time frame: First dose of tremelimumab through 3 months after the last dose of study medication

  9. MEDI4736 area under the concentration-curve

    Time frame: First dose of MEDI4736 through 3 months after the last dose of study medication

  10. Tremelimumab area under the concentration-curve

    Time frame: First dose of tremelimumb through 3 months after the last dose of study medication

  11. Number of subjects that develop changes in detectable antidrug antibodies to tremelimumab

    Time frame: First dose of tremelimumab through 6 months after the last dose of study medication

Other outcomes

  1. Changes in Biomarkers

    Evaluate biomarkers that may correlate with clinical activity of MEDI4736 monotherapy and in combination with tremelimumab

    Time frame: Screening through 3 months after the last patient receives the first dose of study medication

  2. Change from Baseline in Patient-Reported Outcomes

    Time frame: Screening through 5 years after the last patient receives the first dose of study medication

07

Study locations

23 sites
  • Research Site
    Scottsdale, Arizona 85258, United States
  • Research Site
    La Jolla, California 92093, United States
  • Research Site
    Los Angeles, California 90025, United States
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    San Francisco, California 94143, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    New Haven, Connecticut 06520, United States
  • Research Site
    Orlando, Florida 32806, United States
  • Research Site
    Chicago, Illinois 60611, United States
  • Research Site
    Fairway, Kansas 66205, United States
  • Research Site
    New Orleans, Louisiana 70112, United States
  • Research Site
    Baltimore, Maryland 21287, United States
  • Research Site
    Detroit, Michigan 48201, United States
  • Research Site
    Minneapolis, Minnesota 55455, United States
  • Research Site
    New York, New York 10016, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Portland, Oregon 97213, United States
  • Research Site
    Philadelphia, Pennsylvania 19111, United States
  • Research Site
    Greenville, South Carolina 29605, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Fairfax, Virginia 22031, United States
  • Research Site
    London, Ontario N6A 4L6, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2014 to primary completion in Sep 2017, 35 months.

Of 154 industry-sponsored phase 1 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 72. This study's 35 months is below that.

Counting every sponsor, half of 270 studies reached it within 49 months; a quarter within 33 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2014
First posted
Oct 13, 2014
StartActual
Oct 15, 2014
Primary completionActual
Sep 21, 2017
CompletionActual
Sep 21, 2017
Last update
Oct 23, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02262741
Lead sponsor
MedImmune LLC
Responsible party
Sponsor
First posted
Oct 13, 2014
Start date
Oct 15, 2014
Primary completion
Sep 21, 2017
Completion
Sep 21, 2017
Last update
Oct 23, 2017

Study contacts

MedImmune LLC
study director · MedImmune LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Tremelimumab

Start the discussion